Allocation of D-series shares
Celon Pharma has completed its book – building process. Investors will be taking over all Offered Shares.
On 01 July 2021 Celon Pharma S.A. received the decision on approval of the prospectus by the Polish Financial Supervision Authority and published its prospectus in connection with its public offering of D-series shares (the “Offering”). The maximum price in the Offering was set at PLN 45 per share. The Company intends to issue up to 6,000,000 shares and obtain EUR 60 million to finance development of its clinical pipeline and for other corporate purposes, over the course of the next two years.
List of shareholders holding at least 5% of the votes at the Annual General Meeting of the Company held on June 29, 2021
Resolutions adopted by the Annual General Meeting of Celon Pharma S.A. on June 29, 2021
Resolution of the Annual General Meeting on the payment of the dividend
Supplementing the documentation for the Ordinary General Meeting of Celon Pharma S.A. convened to take place on June 29, 2021
adoption of a resolution of the Company’s Management Board on amending the resolution on the share capital increase as part of its authorized capital
Signing of a letter of intent on commencing cooperation with Tarchomińskie Zakłady Farmaceutyczne S.A.
Status update of the phase II clinical trial on an esketamine-based drug in patients with bipolar depression